- Adamas Pharmaceuticals recently reported its Q3 earnings with a slight beat on EPS and a slight miss on revenue. The company did report record product sales for GOCOVRI.
- Adamas looks to have found a rhythm for GOCOVRI and the commericial numbers continue to improve. In addition,i t is now collecting royalties for NAMZARIC.
- After making some drastic moves to manage my Adamas position, I have decided to reload on top of my core position in anticipation that the company will be able to breakeven.
For further details see:
Adamas Pharmaceuticals: Unjustified Sell-Off Following Another Strong Quarter